Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
STAAR Surgical Company faces an active proxy campaign led by Broadwood Partners, L.P., which opposes the proposed acquisition of STAAR by Alcon Inc. Broadwood, which reports owning 30.2% of STAAR’s outstanding common stock, is soliciting votes on a GREEN proxy card for a special meeting where shareholders will vote on the Alcon transaction, urging a vote "AGAINST" the deal.
Broadwood’s attached letter to STAAR’s Board states its belief that the transaction undervalues the company and that STAAR could be worth at least $50 per share if run in what it views as the best interest of shareholders. Broadwood also signals plans to call a separate special meeting to remove certain directors, using another GREEN proxy card, which it describes as distinct from the merger vote. The materials emphasize Broadwood’s long involvement with STAAR and express support for STAAR remaining independent in the near term.
Broadwood Partners and other shareholders of STAAR Surgical are mounting a proxy campaign against the company’s proposed sale to Alcon and preparing a separate effort to remove directors. They have filed materials urging stockholders to use a GREEN proxy card at a special meeting on
Broadwood highlights updated reports from proxy advisors. Glass Lewis and Egan-Jones recommend voting “AGAINST” the transaction, while ISS cites a “deeply flawed” initial sale process, uncertainty about the go-shop and difficulty assessing the offer, yet notes it would not necessarily be unreasonable for shareholders to remain opposed. Broadwood argues the deal undervalues STAAR and criticizes the board’s process.
A separate letter from Yunqi Capital, a
Yunqi Capital, a 5.1% shareholder of STAAR Surgical, is urging investors to vote against the amended cash acquisition of STAAR by Alcon at $30.75 per share. In a detailed letter, Yunqi aligns with Glass Lewis’s continued recommendation against the deal and notes that ISS, while now supporting the merger, acknowledged it would not be unreasonable for shareholders to oppose it. Yunqi criticizes the robustness of STAAR’s go-shop process, pointing to a well-known potential buyer that appeared during the go-shop at a higher indicative price and was later publicly named by STAAR, which Yunqi believes discouraged that party.
Yunqi argues that STAAR’s standalone prospects remain attractive, citing proprietary ICL technology, global distribution, and strong demand trends, including an upcoming China launch of the EVO ICL V5 product line in January 2026 that it expects to carry about a 30–70% price premium over existing ICLs. Yunqi plans to vote its own shares against the merger and encourages other shareholders to do the same, while disclosing that its funds may continue to trade STAAR shares and derivatives over time.
STAAR Surgical's Chief Legal Officer, Nathnaniel B. Sisitsky, reported an equity transaction involving company common stock. On December 11, 2025, restricted stock units granted on December 11, 2023 vested as to 7,312 shares.
Upon vesting, 2,616 shares of common stock were withheld to satisfy taxes at a reported price of $24.68 per share. After this tax withholding, Sisitsky beneficially owned 22,812 shares of STAAR Surgical common stock, which includes previously granted RSUs that are still subject to future vesting.
Broadwood Partners, a significant STAAR Surgical shareholder, is campaigning against STAAR’s proposed acquisition by Alcon. Broadwood highlights that proxy advisory firm Glass Lewis has reaffirmed its recommendation that shareholders vote 'AGAINST' the transaction and is urging investors to use its GREEN proxy card at the special meeting, now postponed to December 19, 2025.
Broadwood also plans a separate special meeting where shareholders would vote on removing members of the STAAR board and any related proposals. The group is directing shareholders to its website, LetSTAARShine.com, and to SEC materials for detailed information and is reminding holders that a later-dated proxy voting against the deal will override any prior vote.
Broadwood Partners, which owns 30.2% of STAAR Surgical Company, is leading a proxy campaign urging shareholders to vote against STAAR’s proposed cash sale to Alcon at $30.75 per share at the special meeting currently set for December 19, 2025.
Broadwood argues the revised offer still undervalues STAAR, noting that Alcon previously indicated willingness to pay $58 per share and later $55 plus a contingent value right of up to $7 per share. Its materials highlight two recent quarters of better-than-expected results, management forecasts for roughly 10% annual net sales growth from 2026 to 2030 and adjusted EBITDA margins above 30% by 2027, and a balance sheet with nearly $200 million of cash and no debt. Broadwood contends STAAR can create greater value as a standalone company and is also preparing a separate campaign to refresh the board if the merger is rejected.
Alcon and STAAR Surgical have agreed to an amended all-cash merger under which Alcon will acquire all outstanding STAAR shares for $30.75 per share, valuing the equity at about $1.6 billion.
The revised price adds roughly $150 million of equity value and represents a 74% premium to STAAR’s 90-day volume-weighted average price and a 66% premium to the August 4, 2025 closing price. Both boards have approved the deal, and STAAR’s board recommends that stockholders approve the transaction.
A prior “go-shop” process ended without a superior offer. Alcon plans to fund the purchase with short- and long-term credit facilities and expects the transaction to be accretive to earnings in year two, with closing anticipated in early 2026, subject to regulatory and STAAR stockholder approvals and other customary conditions.
Broadwood Partners, L.P., which owns 30.2% of STAAR Surgical Company, has filed additional proxy materials opposing STAAR’s proposed sale to Alcon Inc. The materials note that proxy advisory firm Egan-Jones has reaffirmed its recommendation that shareholders vote “AGAINST” the merger on the GREEN proxy card and reference broad opposition to the deal.
Broadwood’s open letter explains why it believes the transaction’s price, timing and sale process are inadequate and argues that STAAR’s standalone value is higher, citing STAAR’s filings that Alcon was willing to pay approximately twice as much per share on two occasions in 2024. Broadwood is also moving to call a separate special meeting to remove three directors it views as most associated with the Alcon transaction, while continuing to urge shareholders to vote against the merger at the special meeting currently postponed to December 19, 2025.
STAAR Surgical Company reported that it issued a press release announcing the results of its “go-shop” process related to its previously announced merger agreement with Alcon Research, LLC and Rascasse Merger Sub, Inc. The go-shop period, established under an amendment to the merger agreement, expired at 11:59 p.m. Eastern Time on December 6, 2025.
The company explains that the proposed transaction is still subject to approval by its stockholders, required regulatory clearances and other closing conditions, and it points investors to its definitive proxy statement and other SEC filings for detailed information, including risk factors describing circumstances that could delay, terminate or otherwise affect completion of the merger.
Broadwood Partners, L.P. and related parties reported open-market purchases of STAAR Surgical (STAA) common stock. On 11/19/2025, they purchased 309,132 shares at a weighted average price of
Following these transactions, Broadwood Partners directly beneficially owned 15,019,491 shares of common stock, and 25,900 shares were directly owned by Neal C. Bradsher. The reporting persons include Broadwood Partners, L.P., Broadwood Capital, Inc. and Neal C. Bradsher, who is identified as a director and 10% owner. The parties state that each disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
